Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6716576 | 0.93 | PPARG (0.46) | NPC1SMN1; SMN2RAB9AHCAR2HPGD | |
| SCHEMBL6713067 | 0.93 | NPC1 (0.45) | NPC1SMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL6715150 | 0.92 | HCAR2 (0.48) | NPC1SMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL6712975 | 0.91 | GCG (0.47) | NPC1SMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL6715209 | 0.91 | GCG (0.51) | NPC1SMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL6722193 | 0.90 | NPC1 (0.54) | NPC1SMN1; SMN2RAB9AALDH1A1HCAR2 | |
| SCHEMBL6715977 | 0.89 | PPARA (0.50) | NPC1SMN1; SMN2RAB9AALDH1A1EPHX2 | |
| SCHEMBL6713405 | 0.87 | GCG (0.44) | NPC1SMN1; SMN2RAB9AHCAR2HPGD | |
| SCHEMBL6713127 | 0.86 | NPC1 (0.52) | NPC1SMN1; SMN2RAB9AHPGDMAPT | |
| SCHEMBL6713649 | 0.85 | NPC1 (0.55) | NPC1SMN1; SMN2RAB9AEPHX2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | SANKYO COMPANY, LTD (JP) | 2004-01-08 | — | — | US | disclosed |
| US-6528525-B1 | Amidocarboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-03-04 | — | — | US | disclosed |
| EP-1026149-A1 | AMIDOCARBOXYLIC ACID DERIVATIVES | Sankyo Company Limited (JP) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006141-A1 | Amidocarboxylic acid compounds | NR1H2, AGK, APOL1 | NPC1 812/4885SMN1; SMN2 4310/4885RAB9A 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.